CD74 expression and its therapeutic potential in thyroid carcinoma

Endocrine-Related Cancer

Volumn 22, Issue 2, 2015, Pages 179-190

  Cheng, Shih Ping ^a,b,c   Liu, Chien Liang ^a,b   Chen, Ming Jen ^a,c   Chien, Ming Nan ^a,b   Leung, Ching Hsiang ^a,b   Lin, Chi Hsin ^a   Hsu, Yi Chiung ^d   Lee, Jie Jen ^a,b,c  

^a MACKAY MEMORIAL HOSPITAL   (Taiwan)

^b NURSING AND MANAGEMENT COLLEGE   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^d INSTITUTE OF STATISTICAL SCIENCE   (Taiwan)

Author keywords

Antibody; CD74; Macrophage migration inhibitory factor; Thyroid cancer

Indexed keywords

ADENOSINE PHOSPHATE; ANTI CD74 ANTIBODY; ANTINEOPLASTIC AGENT; CD74 ANTIGEN; MACROPHAGE MIGRATION INHIBITION FACTOR; NEUTRALIZING ANTIBODY; PROTEIN KINASE B; RECOMBINANT MACROPHAGE MIGRATION INHIBITION FACTOR; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN; ANTIBODY; B LYMPHOCYTE ANTIGEN; HLA ANTIGEN CLASS 2; INVARIANT CHAIN; ISOMERASE; MIF PROTEIN, HUMAN; TRANSCRIPTOME;

ADENOMA; ADULT; ADVANCED CANCER; ANAPLASTIC THYROID CANCER; ARTICLE; CANCER CELL; CANCER INHIBITION; CANCER STAGING; CANCER SURVIVAL; CANCER THERAPY; CELL GROWTH; CELL INVASION; CELL MIGRATION; CLINICAL EVALUATION; COLONY FORMATION; DISEASE ASSOCIATION; DRUG EFFECT; ENZYME ACTIVATION; FEMALE; FOLLICULAR ADENOMA; FOLLICULAR CARCINOMA; GENE OVEREXPRESSION; GENE TARGETING; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; PAPILLARY THYROID CARCINOMA CELL; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; STAINING; THYROID CARCINOMA; TUMOR INVASION; TUMOR VOLUME; CARCINOMA; CELL MOTION; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; METABOLISM; PATHOLOGY; THYROID GLAND; THYROID TUMOR; TUMOR CELL LINE; WOUND HEALING;

ANTIBODIES; ANTIGENS, DIFFERENTIATION, B-LYMPHOCYTE; CARCINOMA; CELL LINE, TUMOR; CELL MOVEMENT; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; INTRAMOLECULAR OXIDOREDUCTASES; MACROPHAGE MIGRATION-INHIBITORY FACTORS; THYROID GLAND; THYROID NEOPLASMS; TRANSCRIPTOME; TUMOR BURDEN; WOUND HEALING;

EID: 84929312785     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-14-0269     Document Type: Article

References (43)

1. Borghese F & Clanchy FI 2011 CD74: an emerging opportunity as a therapeutic target in cancer and autoimmune disease. Expert Opinion on Therapeutic Targets 15 237-251. (doi:10.1517/14728222.2011.550879)
2. Bucala R & Donnelly SC 2007 Macrophage migration inhibitory factor: a probable link between inflammation and cancer. Immunity 26 281-285. (doi:10.1016/j.immuni.2007.03.005)
3. Chang YC, Hsu YC, Liu CL, Huang SY, Hu MC & Cheng SP 2014 Local anesthetics induce apoptosis in human thyroid cancer cells through the mitogen-activated protein kinase pathway. PLoS ONE 9 e89563. (doi:10.1371/journal.pone.0089563)
4. Cheng RJ, Deng WG, Niu CB, Li YY & Fu Y 2011a Expression of macrophage migration inhibitory factor and CD74 in cervical squamous cell carcinoma. International Journal of Gynecological Cancer 21 1004-1012. (doi:10.1097/IGC.0b013e31821c45b7)
5. Cheng SP, Yin PH, Hsu YC, Chang YC, Huang SY, Lee JJ & Chi CW 2011b Leptin enhances migration of human papillary thyroid cancer cells through the PI3K/AKT and MEK/ERK signaling pathways. Oncology Reports 26 1265-1271. (doi:10.3892/or.2011.1388)
6. Cheng SP, Liu CL, Hsu YC, Chang YC, Huang SY & Lee JJ 2012 Regulation of leptin receptor expression in human papillary thyroid cancer cells. Biomedicine & Pharmacotherapy 66 469-473. (doi:10.1016/j.biopha.2012.03.008)
7. Cheng SP, Liu CL, Hsu YC, Chang YC, Huang SY & Lee JJ 2013 Expression and biologic significance of adiponectin receptors in papillary thyroid carcinoma. Cell Biochemistry and Biophysics 65 203-210. (doi:10.1007/s12013-012-9419-1)
8. Govindan SV, Cardillo TM, Sharkey RM, Tat F, Gold DV & Goldenberg DM 2013 Milatuzumab-SN-38 conjugates for the treatment of CD74+ cancers. Molecular Cancer Therapeutics 12 968-978. (doi:10.1158/1535-7163.MCT-12-1170)
9. Hahn-Windgassen A, Nogueira V, Chen CC, Skeen JE, Sonenberg N & Hay N 2005 Akt activates the mammalian target of rapamycin by regulating cellular ATP level and AMPK activity. Journal of Biological Chemistry 280 32081-32089. (doi:10.1074/jbc.M502876200)
10. Hansen HJ, Ong GL, Diril H, Valdez A, Roche PA, Griffiths GL, Goldenberg DM & Mattes MJ 1996 Internalization and catabolism of radiolabelled antibodies to the MHC class-II invariant chain by B-cell lymphomas. Biochemical Journal 320 293-300.
11. Haugen BR & Sherman SI 2013 Evolving approaches to patients with advanced differentiated thyroid cancer. Endocrine Reviews 34 439-455. (doi:10.1210/er.2012-1038)
12. Hay ID, Bergstralh EJ, Goellner JR, Ebersold JR & Grant CS 1993 Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery 114 1050-1057.
13. He H, Jazdzewski K, Li W, Liyanarachchi S, Nagy R, Volinia S, Calin GA, Liu CG, Franssila K, Suster S et al. 2005 The role of microRNA genes in papillary thyroid carcinoma. PNAS 102 19075-19080. (doi:10.1073/pnas.0509603102)
14. Hebrant A, Dom G, Dewaele M, Andry G, Tresallet C, Leteurtre E, Dumont JE & Maenhaut C 2012 mRNA expression in papillary and anaplastic thyroid carcinoma: molecular anatomy of a killing switch. PLoS ONE 7 e37807. (doi:10.1371/journal.pone.0037807)
15. Henne C, Schwenk F, Koch N & Moller P 1995 Surface expression of the invariant chain (CD74) is independent of concomitant expression of major histocompatibility complex class II antigens. Immunology 84 177-182.
16. Huang X, Wullschleger S, Shapiro N, McGuire VA, Sakamoto K, Woods YL, McBurnie W, Fleming S & Alessi DR 2008 Important role of the LKB1-AMPK pathway in suppressing tumorigenesis in PTEN-deficient mice. Biochemical Journal 412 211-221. (doi:10.1042/BJ20080557)
17. Kaufman JL, Niesvizky R, Stadtmauer EA, Chanan-Khan A, Siegel D, Horne H, Wegener WA & Goldenberg DM 2013 Phase I, multicentre, dose-escalation trial of monotherapy with milatuzumab (humanized anti-CD74 monoclonal antibody) in relapsed or refractory multiple myeloma. British Journal of Haematology 163 478-486. (doi:10.1111/bjh.12565)
18. Kim KY, Baek A, Hwang JE, Choi YA, Jeong J, Lee MS, Cho DH, Lim JS, Kim KI & Yang Y 2009 Adiponectin-activated AMPK stimulates dephosphorylation of AKT through protein phosphatase 2A activation. Cancer Research 69 4018-4026. (doi:10.1158/0008-5472.CAN-08-2641)
19. Kindt N, Lechien JR, Nonclercq D, Laurent G & Saussez S 2014 Involvement of CD74 in head and neck squamous cell carcinomas. Journal of Cancer Research and Clinical Oncology 140 937-947. (doi:10.1007/s00432-014-1648-9)
20. Klubo-Gwiezdzinska J, Costello J Jr, Patel A, Bauer A, Jensen K, Mete M, Burman KD, Wartofsky L & Vasko V 2013 Treatment with metformin is associated with higher remission rate in diabetic patients with thyroid cancer. Journal of Clinical Endocrinology and Metabolism 98 3269-3279. (doi:10.1210/jc.2012-3799)
21. Lamki L, Row VV & Volpe R 1973 Cell-mediated immunity in Graves' disease and in Hashimoto's thyroiditis as shown by the demonstration of migration inhibition factor (MIF). Journal of Clinical Endocrinology and Metabolism 36 358-364. (doi:10.1210/jcem-36-2-358)
22. Leng L, Metz CN, Fang Y, Xu J, Donnelly S, Baugh J, Delohery T, Chen Y, Mitchell RA & Bucala R 2003 MIF signal transduction initiated by binding to CD74. Journal of Experimental Medicine 197 1467-1476. (doi:10.1084/jem.20030286)
23. Lin JD & Chao TC 2005 Vascular endothelial growth factor in thyroid cancers. Cancer Biotherapy & Radiopharmaceuticals 20 648-661. (doi:10.1089/cbr.2005.20.648)
24. Lippitz BE 2013 Cytokine patterns in patients with cancer: a systematic review. Lancet. Oncology 14 e218-e228. (doi:10.1016/S1470-2045(12)70582-X)
25. Liu CL, Cheng SP, Lin HW & Lai YL 2014 Risk of thyroid cancer in patients with thyroiditis: a population-based cohort study. Annals of Surgical Oncology 21 843-849. (doi:10.1245/s10434-013-3363-1)
26. Lue H, Thiele M, Franz J, Dahl E, Speckgens S, Leng L, Fingerle-Rowson G, Bucala R, Luscher B & Bernhagen J 2007 Macrophage migration inhibitory factor (MIF) promotes cell survival by activation of the Akt pathway and role for CSN5/JAB1 in the control of autocrine MIF activity. Oncogene 26 5046-5059. (doi:10.1038/sj.onc.1210318)
27. Manning BD & Cantley LC 2007 AKT/PKB signaling: navigating downstream. Cell 129 1261-1274. (doi:10.1016/j.cell.2007.06.009)
28. Martin-Ventura JL, Madrigal-Matute J, Munoz-Garcia B, Blanco-Colio LM, Van Oostrom M, Zalba G, Fortuno A, Gomez-Guerrero C, Ortega L, Ortiz A et al. 2009 Increased CD74 expression in human atherosclerotic plaques: contribution to inflammatory responses in vascular cells. Cardiovascular Research 83 586-594. (doi:10.1093/cvr/cvp141)
29. Meyer-Siegler KL, Iczkowski KA, Leng L, Bucala R & Vera PL 2006 Inhibition of macrophage migration inhibitory factor or its receptor (CD74) attenuates growth and invasion of DU-145 prostate cancer cells. Journal of Immunology 177 8730-8739. (doi:10.4049/jimmunol.177.12.8730)
30. Miller EJ, Li J, Leng L, McDonald C, Atsumi T, Bucala R & Young LH 2008 Macrophage migration inhibitory factor stimulates AMP-activated protein kinase in the ischaemic heart. Nature 451 578-582. (doi:10.1038/nature06504)
31. Nagata S, Jin YF, Yoshizato K, Tomoeda M, Song M, Iizuka N, Kitamura M, Takahashi H, Eguchi H, Ohigashi H et al. 2009 CD74 is a novel prognostic factor for patients with pancreatic cancer receiving multimodal therapy. Annals of Surgical Oncology 16 2531-2538. (doi:10.1245/s10434-009-0532-3)
32. Ogrinc T, Dolenc I, Ritonja A & Turk V 1993 Purification of the complex of cathepsin L and the MHC class II-associated invariant chain fragment from human kidney. FEBS letters 336 555-559. (doi:10.1016/0014-5793(93)80875-U)
33. Phay JE & Ringel MD 2013 Metastatic mechanisms in follicular cell-derived thyroid cancer. Endocrine-Related Cancer 20 R307-R319. (doi:10.1530/ERC-13-0187)
34. Qi D, Atsina K, Qu L, Hu X, Wu X, Xu B, Piecychna M, Leng L, Fingerle-Rowson G, Zhang J et al. 2014 The vestigial enzyme D-dopachrome tautomerase protects the heart against ischemic injury. Journal of Clinical Investigation 124 3540-3550. (doi:10.1172/JCI73061)
35. Ren Y, Law S, Huang X, Lee PY, Bacher M, Srivastava G & Wong J 2005 Macrophage migration inhibitory factor stimulates angiogenic factor expression and correlates with differentiation and lymph node status in patients with esophageal squamous cell carcinoma. Annals of Surgery 242 55-63. (doi:10.1097/01.sla.0000168555.97710.bb)
36. Schweppe RE, Klopper JP, Korch C, Pugazhenthi U, Benezra M, Knauf JA, Fagin JA, Marlow LA, Copland JA, Smallridge RC et al. 2008 Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification. Journal of Clinical Endocrinology and Metabolism 93 4331-4341. (doi:10.1210/jc.2008-1102)
37. Shinohara M, Chung YJ, Saji M & Ringel MD 2007 AKT in thyroid tumorigenesis and progression. Endocrinology 148 942-947. (doi:10.1210/en.2006-0937)
38. Sliwkowski MX & Mellman I 2013 Antibody therapeutics in cancer. Science 341 1192-1198. (doi:10.1126/science.1241145)
39. Starlets D, Gore Y, Binsky I, Haran M, Harpaz N, Shvidel L, Becker-Herman S, Berrebi A & Shachar I 2006 Cell-surface CD74 initiates a signaling cascade leading to cell proliferation and survival. Blood 107 4807-4816. (doi:10.1182/blood-2005-11-4334)
40. Verjans E, Noetzel E, Bektas N, Schutz AK, Lue H, Lennartz B, Hartmann A, Dahl E & Bernhagen J 2009 Dual role of macrophage migration inhibitory factor (MIF) in human breast cancer. BMC Cancer 9 230. (doi:10.1186/1471-2407-9-230)
41. Winner M, Koong AC, Rendon BE, Zundel W & Mitchell RA 2007 Amplification of tumor hypoxic responses by macrophage migration inhibitory factor-dependent hypoxia-inducible factor stabilization. Cancer Research 67 186-193. (doi:10.1158/0008-5472.CAN-06-3292)
42. Xu X, Wang B, Ye C, Yao C, Lin Y, Huang X, Zhang Y & Wang S 2008 Overexpression of macrophage migration inhibitory factor induces angiogenesis in human breast cancer. Cancer Letters 261 147-157. (doi:10.1016/j.canlet.2007.11.028)
43. Zheng YX, Yang M, Rong TT, Yuan XL, Ma YH, Wang ZH, Shen LS & Cui L 2012 CD74 and macrophage migration inhibitory factor as therapeutic targets in gastric cancer. World Journal of Gastroenterology 18 2253-2261. (doi:10.3748/wjg.v18.i18.2253)